Action Roche - 1RO

Roche Holding AG (1RO) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

362,80

( -0,87% )

Prix Achat

183,00

Prix Vente

549,00

Volume échangé

362,40 Fourchette du Jour 362,80

270,00 Plage de 52 semaines 422,00

Cap du marché

288,65B

Clôture Veille

366,00

Ouverture

362,40

Dernière Transaction

362.8

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

1 021 214 €

Actions en circulation

795 617 637

Rendement du Dividende (LTM)

9,8 (3,11%)

Ratio Cours sur Bénéfices

20,63

Bénéfice par action (BPA)

16,04

Chiffre d'affairess (LTM)

63,36B

Bénéfice net (LTM)

12,88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland. Show more

Secteur

Industrie

Site Web

www.roche.com

Siège social

Basel, Switzerland

Fondé

1896

Roche Holding AG est coté dans le secteur de la Italian Stock Exchange avec le ticker 1RO. Le dernier cours de clôture d'Roche était de 366,00 €. Au cours de la dernière année, les actions de Roche ont été négociées dans une fourchette de prix de 270,00 € à 422,00 €.

Roche compte actuellement 795 617 637 actions en circulation. La capitalisation boursière d'Roche est de 288,65 € milliard. Roche a un ratio cours/bénéfice (ratio PE) de 20.63.

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive...

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions Late-breaking Phase II...

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management Roche introduces the...

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer New...

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) Elecsys® pTau217...

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics PathAI’s best-in-class Image Management...

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 New real-world data confirm Vabysmo’s potent...

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5...

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in...

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS Late-breaking Phase III...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-5.4	-1.46659424226	368.2	368.2	341.6	40	346.48643216	DE
4	9	2.54381006218	353.8	377	341.6	39	358.83964194	DE
12	-1.2	-0.32967032967	364	377.8	338	23	357.21908517	DE
26	16.8	4.85549132948	346	422	334	18	366.85802651	DE
52	52.8	17.0322580645	310	422	270	13	350.78791396	DE
156	56.8	18.5620915033	306	422	270	12	350.07265993	DE
260	56.8	18.5620915033	306	422	270	12	350.07265993	DE

1RO - Frequently Asked Questions (FAQ)

What is the current Roche Holding AG share price?

The current share price of Roche Holding AG is 362,80 €

How many Roche Holding AG shares are in issue?

Roche Holding AG has 795 617 637 shares in issue

What is the market cap of Roche Holding AG?

The market capitalisation of Roche Holding AG is EUR 288,65B

What is the 1 year trading range for Roche Holding AG share price?

Roche Holding AG has traded in the range of 270,00 € to 422,00 € during the past year

What is the PE ratio of Roche Holding AG?

The price to earnings ratio of Roche Holding AG is 20,63

What is the cash to sales ratio of Roche Holding AG?

The cash to sales ratio of Roche Holding AG is 4,16

What is the registered address of Roche Holding AG?

The registered address for Roche Holding AG is Grenzacherstrasse 124, Basel, Basel-Stadt, 4070

What is the Roche Holding AG website address?

The website address for Roche Holding AG is www.roche.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roche Holding AG (1RO)

Roche Holding AG (1RO) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Roche Holding AG

1RO Dernières nouvelles

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

1RO - Frequently Asked Questions (FAQ)

1RO Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités